Ultragenyx Pharmaceuticalは、Rare Pediatric Disease Priority Review Voucherを2億1000万ドルで売却するための確定的な合意に達しました。この取引は、適用されるHart-Scott-Rodino待機期間の経過を含む一般的なクロージング条件に従って進行中です。
なぜ重要か. この売却により、Ultragenyxは薬剤開発プログラムのための大規模な非希薄化資金を得ることができ、さらに移譲可能なFDA審査バウチャーの金銭的価値を示すことにもなります。
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million.
NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV upon U.S.…
The closing of the PRV transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act.
